Phase I
Three- and four-year data continued to show reduction in amyloid plaque and to suggest a slowing of the rate of clinical decline in patients.
Initial data from the first cohort expected in first half of 2019
In its recent third-quarter report, Cambridge, Mass.-based Intellia Therapeutics indicated it is delaying its submission of an Investigational New Drug (IND) application until 2020, from late 2019.
The United Kingdom is calling for greater clinical trial transparency after a government committee released a report that indicates that data from about half of all clinical trials in that country are not published, raising concerns over research integrity and risks to human health.
Galapagos NV announces topline interim results of Part 1 of the FALCON trial in cystic fibrosis (CF).
Booster Vaccination After ~7 Years Resulted in 600-fold Increase in Antibody Response
Santhera Pharmaceuticals announces the start of a Phase Ib/IIa multiple ascending dose (MAD) trial with POL6014 in patients with cystic fibrosis (CF).
Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announces that data from a phase I study assessing the safety and tolerability of its lead drug candidate SNF472 in haemodialysis patients has been published in the British Journal of Clinical Pharmacology.
Routine corticosteroid treatment correlates with increased mortality and decreased Traumakine efficacy
ASLAN Pharmaceuticals today announced the presentation of new data from an ongoing phase 1 study to determine the safety, tolerability and maximum tolerated dose (MTD) of varlitinib in combination with oxaliplatin and capecitabine (COX) or oxaliplatin and 5-FU (FOL) in advanced solid tumours.
PRESS RELEASES